phase readout
saveNCT02926690: Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
RECRUITINGupdated 1mo ago
community read0 votes
Sponsor: OncoTherapy Science, Inc.. Phase: PHASE1. Conditions: Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
view source ↗
comments(0)
5-min edit window · permanent after that